{name}
{subtitle}
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~84 mi. (Oviedo, Spain, +93 more cities)
facility
Hospital Universitario Central de Asturias ( Site 0654)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~84 mi. (Lugo, Spain, +130 more cities)
facility
Hospital Universitario Lucus Augusti ( Site 0852)
drug
BCG solution, +1 more drug
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~84 mi. (Oviedo, Spain, +199 more cities)
facility
Hospital Central de Asturias ( Site 0667)
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
city
~84 mi. (Oviedo, Spain, +45 more cities)
facility
Hospital Universitario General de Asturias ( Site 1601)
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +2 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~84 mi. (Oviedo, Spain, +122 more cities)
facility
Hospital Universitario Central de Asturias ( Site 1900)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types